TalkMed Group (SGX:5G3) EPS (Diluted) : S$0.03 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is TalkMed Group EPS (Diluted)?

TalkMed Group's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was S$0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.03.

TalkMed Group's EPS (Basic) for the six months ended in Dec. 2023 was S$0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.03.

TalkMed Group's EPS without NRI for the six months ended in Dec. 2023 was S$0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was S$0.03.

During the past 12 months, TalkMed Group's average EPS without NRIGrowth Rate was 8.70% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 9.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, TalkMed Group's highest 3-Year average EPS without NRI Growth Rate was 9.60% per year. The lowest was -97.90% per year. And the median was -7.20% per year.

TalkMed Group EPS (Diluted) Historical Data

The historical data trend for TalkMed Group's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TalkMed Group EPS (Diluted) Chart

TalkMed Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

Get a 7-Day Free Trial

0.03

0.02

TalkMed Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of TalkMed Group's EPS (Diluted)

For the Medical Care Facilities subindustry, TalkMed Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TalkMed Group's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TalkMed Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where TalkMed Group's PE Ratio falls into.

TalkMed Group EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

TalkMed Group's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(32.176	-	0)	/	1331.827
	=	0.02

TalkMed Group's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(17.904	-	0)	/	1332.101
	=	0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was S$0.03

TalkMed Group (SGX:5G3) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

TalkMed Group EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of TalkMed Group's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

TalkMed Group (SGX:5G3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TalkMed Group Ltd (SGX:5G3) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Mount Elizabeth, Mount Elizabeth Hospital Level 2, Singapore, SGP, 228510

Website

https://www.talkmed.com.sg

TalkMed Group Ltd operates as an investment holding company. It is a provider of medical oncology, stem cell transplants and palliative care services, serving patients in Singapore and the region. Outside Singapore, the Group operates in Vietnam, Hong Kong and the People's Republic of China. The activities of the company are the provision of medical oncology services and palliative care healthcare services in Singapore. It is organized into three reportable operating segments, Oncology Services, Stem Cells Services and Cellular and gene therapy-related products and services. The company has operational footprints across Singapore, Hong Kong and Vietnam of which Singapore contributes the vast majority of total revenue. It generates maximum revenue from the Oncology services segment.

TalkMed Group (SGX:5G3) Headlines

No Headlines